2024
Long-Term Outcomes of Prostate-Specific Membrane Antigen–PET Imaging of Recurrent Prostate Cancer
Kunst N, Long J, Westvold S, Sprenkle P, Kim I, Saperstein L, Rabil M, Ghaffar U, Karnes R, Ma X, Gross C, Wang S, Leapman M. Long-Term Outcomes of Prostate-Specific Membrane Antigen–PET Imaging of Recurrent Prostate Cancer. JAMA Network Open 2024, 7: e2440591. PMID: 39441595, DOI: 10.1001/jamanetworkopen.2024.40591.Peer-Reviewed Original ResearchConceptsProstate-specific antigenProstate-specific antigen levelPSMA-PETRecurrent prostate cancerBiochemical recurrenceProstate cancerLong-term outcomesProstate-specific membrane antigen positron emission tomographyEvaluation of biochemical recurrenceDetection of biochemical recurrenceLife yearsConventional imagingDefinitive local therapyPSMA PET imagingProstate cancer deathDetection of metastasesRetrospective cohort studyBase case analysisIncremental life-yearsPositron emission tomographyDecision-analytic modelLocal therapyConventional imaging strategiesDelayed treatmentDisease course
2012
An assessment of the collective efforts of clinical trials to provide evidence-based practice guidelines in cancer care.
Lloyd S, Buscariollo D, Gross C, Makarov D, Yu J. An assessment of the collective efforts of clinical trials to provide evidence-based practice guidelines in cancer care. Journal Of Clinical Oncology 2012, 30: 6019-6019. DOI: 10.1200/jco.2012.30.15_suppl.6019.Peer-Reviewed Original ResearchRCT enrollmentMeasures of burdenCancer research effortsNCCN guidelinesNCCN recommendationsEndometrial cancerNational Comprehensive Cancer Network guidelinesEvidence-based practice guidelinesPhase 3 RCTsClinical trial enrollmentPrevalent solid tumorsTrial enrollmentNetwork guidelinesCancer careCNS cancerTreatment recommendationsClinical trialsProstate cancerPractice guidelinesSolid tumorsLife yearsMultivariate analysisMost recommendationsCancer typesCancer